Prulifloxacin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Prulifloxacin API 123447-62-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Prulifloxacin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Prulifloxacin
- Synonyms:
- Cas Number:
- 123447-62-1
- DrugBank number:
- DB11892
- Unique Ingredient Identifier:
- J42298IESW
General Description:
Prulifloxacin, identified by CAS number 123447-62-1, is a notable compound with significant therapeutic applications. Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Classification:
Prulifloxacin belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions, classified under the direct parent group Quinoline carboxylic acids. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Quinolines and derivatives class, specifically within the Quinoline carboxylic acids subclass.
Categories:
Prulifloxacin is categorized under the following therapeutic classes: Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dioxoles, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Prulifloxacin is a type of Enzyme Replacements/modifiers
Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.
Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.
On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.
Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.
The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.
Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.
